logo-loader
RNS
Spectral AI Inc

Spectral MD Holdings - Appointment: V.P of Marketing

RNS Number : 1932I
Spectral MD Holdings, Ltd.
13 April 2022
 

13 April 2022

 

Spectral MD Holdings, Ltd

("Spectral MD" or the "Company" or the Group")

 

Appointment of Christine Marks as Vice President of Marketing and Commercialisation

 

Seasoned marketing & commercialisation professional to help bolster commercialisation expertise

 

LONDON, U.K AND DALLAS, TX, U.S. Spectral MD Holdings, Ltd. (AIM: SMD), a predictive analytics company that develops proprietary AI algorithms and optical technology for faster and more accurate treatment decisions in wound care, announces the appointment of Christine Marks as VP of Marketing and Commercialisation with immediate effect.

 

Ms. Marks brings over 20 years of marketing and commercialisation experience to Spectral MD, launching innovations globally at medical device and technology companies. Ms. Marks is an innovative and strategic marketing executive with leadership experience in the medical device, diagnostic, B2B and B2C industries. In addition, Ms. Marks has a successful track record of driving organisational growth through VOC market research, product launch, digital companions and building high performing teams. Ms. Marks has been responsible for transformational commercialisation at high growth companies, where she was responsible for developing and executing key marketing strategies and campaigns.

 

Prior to joining Spectral MD, Ms. Marks has held senior marketing roles across various medical device and technology companies where she has demonstrated ability to increase revenue, brand value, profit, and marketing ROI.  Most recently, Ms. Marks served as Vice President, Sales & Marketing at Monarch Medical Technologies, the maker of the EndoTool® Glucose Management System, where she created account-based marketing strategies outlining focused growth plans and targeted messaging to health systems. Prior to Monarch Medical Technologies, Ms. Marks has held multiple Vice President of Marketing roles in the wound care space, where she has been instrumental in developing successful go-to-market strategies to fuel commercialisation and growth. This experience in the wound care sector will provide a valuable addition to Spectral MD's leadership team as it develops its DeepView® wound imaging platform towards commercialisation.

 

As VP of Marketing and Commercialisation at Spectral MD, Ms. Marks will develop and implement cohesive marketing plans to increase brand awareness, while overseeing marketing strategies and efforts to strengthen Spectral MD's market position and achieve commercial goals.

 

Wensheng Fan, CEO of Spectral MD Holdings, Ltd, said: "We are pleased to strengthen our commercialisation expertise with the addition of Christine to our leadership team. With more than 20 years of experience in healthcare sales, marketing, and commercialisation, Christine will be instrumental in solidifying our marketing and commercialisation strategy as we work towards commercialisation and beyond."

 

"Our continued growth has allowed us to bring these experienced leaders to the company. Christine's expertise is just what we need to scale our growth and position DeepView® for market success."

 

Christine Marks, VP of Marketing and Commercialisation, said: "I am thrilled to be joining an amazing company and a tremendously talented team at such an exciting and transformational time. Spectral MD is a pioneer of disruptive technology that will significantly improve the wound care sector for patients, and I look forward to further elevating the value of this transformative technology."

 

For further information please contact:

 

Spectral MD Holdings, Ltd.

investors.spectralmd.com

Wensheng Fan, Chief Executive Officer

via Walbrook PR

Nils Windler, Chief Financial Officer

 

 

 

SP Angel Corporate Finance LLP (NOMAD and Joint Broker)

Tel: +44 (0)20 3470 0470

Stuart Gledhill/Caroline Rowe (Corporate Finance)

Vadim Alexandre/Rob Rees (Sales & Broking)

 

Stifel Nicolaus Europe Limited (Joint Broker)

Charles Hoare / Ben Maddison / Nick Harland / Will Palmer-Brown

 

 

 

Tel: +44 (0) 20 7710 7600

 

 

Walbrook PR Ltd (Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or spectralMD@walbrookpr.com

Paul McManus / Sam Allen

Alice Woodings

Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258

+44 (0)7407 804 654

     

  

 

About Spectral MD:                                                                                       

We are a dedicated team of forward-thinkers striving to revolutionize the management of wound care by "Seeing the Unknown" ® with our DeepView®  Wound Imaging System.

www.spectralmd.com

info@spectralmd.com

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAEAFLAFSSAEAA
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read